Receptos is a privately held biopharmaceutical company focused on identifying and developing best- and first-in-class GPCR therapeutic candidates through information-driven drug discovery, including GPCR structure. Company co-founders from The Scripps Research Institute are Professors Raymond Stevens, Ph.D., whose pioneering work in GPCR structural biology was a Top 10 Scientific Discovery in 2007, and Hugh Rosen, M.D., Ph.D., Professor of Chemical Physiology and Immunology. Flagship General Partner Doug Cole is on the Board of Directors.

www.receptos.com